Acquisition adds synthetic oxyntomodulin peptides including a candidate for obesity.

Wyeth Pharmaceuticals acquired Thiakis for approximately $30 million. Additional payments of up to $120 million will be payable upon the achievement of certain development milestones.


Thiakis’ lead product candidate, TKS1225, is being studied for the treatment of obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin.


“Thiakis’ research and development program fits well with our goal of addressing the medical burden of obesity in a targeted manner using biologic-based therapies,” says Mikael Dolsten, M.D., Ph.D., president, Wyeth Research.

Previous articleAdolor Shutters Phase III Development of OBD Drug
Next articlePfizer Pays $75M Upfront for European Marketing Licenses from Auxilium